INFECTION CONTROL

HOSPITAL EPIDEMIOLOGY

Volume 11, Number 3 • March 1990

EDITORIAL Medical Ostriches Douglas R. LaBrecque, MD ORIGINAL ARTICLES	126	Brief Report: The Utilization of Influencing Tactics for the Implementation of Infection Control Policies W.H. Seto, MD; S.G. Ong, MD; T.Y. Ching, RN; S.H. Ng, PhD; Y.B. Chu, BSc; W.H. Yung, MD; L.M. Ho, BSc	144
Hepatitis B: Perceptions, Knowledge and Vaccine Acceptance Among Registered Nurses in High-Risk Occupations in a University Hospital Michael R. Spence, MD, MPH; Georgia P. Dash, MS, CIC	129	SPECIAL COMMENTARY Contributions of Epidemiology to Quality Assessment and Monitoring Avedis Donabedian, MD	117
Nosocomial Infection Caused by Xanthomonas maltophilia: A Case-Control Study of Predisposing Factors Linda S. Elting, DrPH; Nancy Khardori, MD, PhD; Gerald P. Bodey, MD; Victor Fainstein, MD	134	CLINICAL PHARMACOLOGY OF ANTIBIOTICS Empiric Antimicrobial Therapy in the Febrile Granulocytopenic Patient Walter T. Hughes, MD	151
Alcohol for Surgical Scrubbing? Elaine L. Larson, PhD; Arlene M. Butz, ScD; Donna L. Gullette, MSN; Barbara A. Laughon, PhD	139	EMPORIATRICS Emporiatrics: The Study of Diseases in Travelers Mary D. Nettleman, MD SHEA NEWSLETTER	157

From SmithKline Biologicals/SK&F



0, 1, 2 Month Dosing Regimen for Certain Populations*

20 mcg recombinant dose helps to ensure immune response in adult patients of all ages

Choice of dosing regimens

Adult dose (mcg)

Standard dosing regimen (0, 1 and 6 months)

New 0, 1, 2 month dosing regimen for certain populations*

Published efficacy data: Neonates born of infected mothers'

VACTRAC[™]—computer software for vaccination tracking and compliance

Bar-coded, unit-dose vials

Lowest cost per dose²

*For those recently exposed to the virus (including needlestick exposure), certain travelers to high-risk areas, and neonates born of infected mothers. When prolonged maintenance of protective antibody titers is desired, a booster dose at month 12 is recommended. †Hepatitis B Vaccine (Recombinant), MSD.

‡Please see brief summary of prescribing information on adjacent page for a complete listing of adverse reactions, contraindications, warnings and precautions.©SmithKline Beckman Corporation, 1990


Lowest Cost Per Dose²

Extensively Tested and Well Tolerated[‡]

State-of-the-art recombinant technology 10 million doses distributed in over 80 countries³

Switch to 'Engerix-B'

Can be used to complete a course of vaccination initiated with another hepatitis B vaccine^{3,4}



https://doi.org/10.1017/S0899823X00082660 Published online by Cambridge University Press

Engerix-B[®]

Hepatitis **B** Vaccine (Recombinant)

See complete prescribing information in SK&F literature or PDR. The following is a brief summary.

INDICATIONS AND USAGE: 'Engerix-B' is indicated for immunization against intection caused by all know subtypes of hepatitis B wrus immunization is recommended in parsons of all ages, especially those who are or will be, al increased risk deposure to hepatitis B wrus.

CONTRAINDICATIONS:Hypersensitivity to yeast or any other component of the vaccine is a contraindication for use of the vaccine

WARNINGS: Do not iguve 'adigmal injections to patients experiencin hypersensitivity alter an 'Engerix-B'injection. (See CONTRAINDICATIONS.)

Hepatitis B has a long incubation period. Hepatitis B vaccination may not prevent hepatitis B infection in individuals who had an unrecognized hepatitis b infection al the time of vaccine administration Additional; Timay not preventintection in individuals who do not achieve protective antibody titers

PRECAUTIONS: General: As with any percutaneous vaccine, keep epinephrine available for use in case of anaphylaxis or anaphylactoidreaction.

As with any vaccine, delay administration, 1 possible, in persons with any febrile illness of active infection

Prognamcy: Pregnancy Category C Animal reproduction studies have not been conducted with Engerix B II is also not known whether Engerix B can cause tetal harm when administered to a pregnant woman or can affect repro duction capacity Give Engerix B to a pregnant woman or yir clearly needed.

Nursing Mothers: It is not known whether 'Engerix-B' is excreted in human mik Because many drugs are excreted in human mik, use caution when giving 'Engerix-B' to a nursing woman.

gring engence to a monitoring worldatt.
Pediatric Usa: 'Engence B' has been shown to be well tolerated and hith by immunogenic in infants and children of all ages. Newborns also respond well; maternally transferred antibodies do not interfere with the active immune response to the vaccine.

ADVERSE REACTIONS: "Engerix-B" is generally well tolerated. During clinical studies involving over 10.000 individuals distributed over all age groups, no senous adverse reactions attributable to vaccine administration were reported. As with any vaccine, however, it is possible that expanded commercal use of the vaccine could reveal rare adverse reactions not observed in chinical studies.

Camical studies. Ten double-blind studies involving 2,252 subjects showed no significant difference in the requency or severity of adverse experiences between Engerix-B' and plasma-derived vaccines. In 36 clinical studies a total of 1,345 does of Engerix B' were administered to 5.071 healthy adults and children who were initially seronegative for hepatitis B markers and healthy neonates. All subjects were monitored for 4 days post-administration. Fequency of overseexperiences tended to decrease with successive doses of Engerix-B' Using a symptom checklist, "the mod lequentity reported adverse reactions are injection site someness (2296), and latigue" (14%). Mher reactions are listed below

Incidence 1% to 10% et injections: Induration; erythema; swelling, fever (>37.5°C); headache': dizziness.*

*Parent or guardian completed forms for children and neonates Neonatal checklist did not include headache. fatigue or dizziness.

Incleance <1% of Injections: Pain; pruntus; ecchymosis; sweating; malaise: chilis; weaknesfuushing; tingjing; hypotension; influenza like symptoms; upper respiratory tract illnesses; nausea; anowxia; abdominal pain/ cramps; vomiting; constipation; diarnhea; hymphadenopathy; pain/stiffness in arm, shoulder or neck; arthralgia; myalgia; back pain; rash urticaria; petechiae; erythema; somnolence; insomnia; irritability; agitation.

Chiele etytinema, Softmitolerit.et: insomma, irmadiniy, agriadutt. Additional adverse experiences have been reported with the commercial use of Engerix B outside the United States. Those listed below are to serve as alerting information to physicians: Anaphykaxis, erythema multiforme including Stevens Johnson syndrome; angioedema, arthritis; tachycardia/palpitations; bronchospasm including asthma-like symptoms; abnormal liver functions; bronchospasm including asthma-like symptoms; abnormal liver functions tests; migraine; syncope; paresis; neuropathy including hypoesthesia, paresthesia, Guillain Baré syndrome and Bell's palsy; transverse myelitis; thrombocytopena; ezezema; purpura; herpes zoster; vertigo, conjunctivitis; keratitisyrisuabilisturbances.

Potential Adverse Experiences. In addition, certain other adverse expenences not observed with "Engerive Bhave been reported with Heptavax B®+ and/or Recombivax HB*+. Those listed below are to serve as alerting information to physicians: optic neuritis.

HOW SUPPLIED:20mcg/mL in Single-Dose Vials in packages 011.10 and 25 vials.

NOC 0007-3860-01(package of 1) NOC 0007-3860-11 (package of 10) NOC 0007-3860-16(package of 25)

10 mcg/0.5 mL in Single-Dose Vials III packages of 1vial. NDC 0007-3859-01(package of 1)

† plasma-derived, Hepatitis B Vaccine, MSD. ‡yeast-derived, Hepatitis B Vaccine, MSD

Manufactured by SmithKline Biologicals, Rixensart, Belgium Distributed by SmithKline Sfrench Laboratories Ott of SmithKline Beckman Corp. Philadelphia, PA 19101

Date d issuance Aug. 1989

BRS-EB:L6

© SmithKline Beckman Corporation, 1969

Engerix-Bis a registered trademark of SmithKline Beckman Corporation

References:

 Poovorawan Y, Sanpavat S. Pongpunlert W, et al: Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBc antigen-positive mothers. JAMA 1989; 261(22):3278-3281.
 Based on Medi-Span^{*} Hospital Formulary Pricing Guide, December 1989. 3. Data on file, SK&F. 4. Bush L. Moonsammy G, Boscia J: Evaluation of initiating a hepatitis B vaccination schedule with one vaccine and completing it with another. *Hepatology* 1989;10:689.

Hats off to first **class** service

At SLACK incorporated we believe our subscribers are first class peopie. That's why we do everything possible to publish first class journals. And, that's why we maintain a TOLL-FREE CUSTOMER SERVICE HOTLINE. For the first class customer service you deserve, call:


I-800-257-8290 Talk to a SLACK Customer Service Representative about:

Subscriptions. Subscribing by phone is quick and easy; it only takes a minute and Visa and Mastercard are accepted.

Renewals. Early subscription renewal helps avoid possible interruptions in service.

Change of Address. Please notify us four weeks in advance to assure prompt delivery to your new address

Questions or Problems. Delivery problems or questions about your subscriptions can be handled instantly.



AND HOSPITAL

EPIDEMIOLOGY

INFECTION CONTROL

Medical Ostriches 126 **EDITORIAL** Douglas R. LaBrecque, MD Hepatitis B: Perceptions, Knowledge and Vaccine 129 ORIGINAL **Acceptance Among Registered Nurses in High-Risk** ARTICLES **Occupations in a University Hospital** Michael R. Spence, MD, MPH; Georgia P. Dash, MS, CIC Nosocomial Infection Caused by Xanthomonas maltophilia: 134 A Case-Control Study of Predisposing Factors Linda S. Elting, DrPH; Nancy Khardori, MD, PhD; Gerald P. Bodey, MD; Victor Fainstein, MD 139 **Alcohol for Surgical Scrubbing?** Elaine L. Larson, PhD; Arlene M. Butz, ScD; Donna L. Gullette, MSN; Barbara A. Laughon, PhD Brief Report: The Utilization of Influencing Tactics for the 144 **Implementation of Infection Control Policies** W.H. Seto, MD; S.G. Ong, MD; T.Y. Ching, RN; S.H. Ng, PhD; Y.B. Chu, BSc; W.H. Yung, MD; L.M. Ho, BSc **Special Commentary** 117 SPECIAL Contributions of Epidemiology to Quality Assessment and SECTIONS Monitoring Avedis Donabedian. MD **Clinical Pharmacology of Antibiotics** 151 **Empiric Antimicrobial Therapy in the Febrile Granulocytopenic** Patient Walter T. Hughes, MD **Emporiatrics** 157 **Emporiatrics: The Study of Diseases in Travelers** Mary D. Nettleman, MD **DEPARTMENTS** SHEA Newsletter **Calendar of Events** 161 164 **Classified Marketplace** 163

The ideas and opinions expressed by contributing authors do not

necessarily reflect those of the editors or publisher.

Publisher: Infection Control and Hospital Epidemiology (ISSN-0899-823X) is published monthly by SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086 Telephone (609) 848-1000

Copyright 1990: All rights reserved No part of this publication may be reproduced without written permission from the publisher

Subscriptions: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated. 4-22-11, Kitakasai, Edogawaku Tokyo 134. Japan Subscription rates In the US and possessions Individual: One year—\$60 00. Two years-\$95 00: Three years—\$125 00. Institutional One year—\$70 00: Two years-\$110 00. Three years—\$150 00; Canada \$18 00 additional each year; all other countries \$30 00 additional each year Single copies of current issues may be obtained for \$8 00, United States and possessions; \$16.00 all other countries

Reprints: All requests to reprint or use material published herein should be addressed to Lester J Robeson, SLACK Incorporated, 6900 Grove Road. Thorofare, NJ 08066. For reprint orders and pTiCeS, contact Joanne Patterson at (609) 848-1000 Authorization to photocopy items for Internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy plus \$15 per page IS paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970 This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works

Change of address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes The publisher cannot accept responsibility for undelivered copies Second-class postage is paid at Thorofare. New Jersey 08086 and additional entry points Postmaster: Send address changes to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086

As of Volume 1, Number 1, INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents—Clinical Practice Hospital Literature Index, Cumulative Index to Nursing and Allied Health Literature, and Nursing Abstracts

EDITORIAL OFFICES Vanderbilt University School of Medicine A-1131 Medical Center North Nashville, TN 37232-2637 (615) 343-1095; (615) 343-1882 (FAX) Email: iche@mcmail.vanderbilt.edu EDITOR Michael D. Decker, MD, MPH MANAGING EDITOR Susan Cantrell STATISTICAL EDITOR Beverly G. Mellen, PhD SENIOR ASSOCIATE EDITORS C. Glen Mayhall, MD Gina Pugliese, RN, MS William Schaffner, MD ASSOCIATE EDITORS Donald A. Goldmann, MD Didier Pittet, MD, MS Andreas Widmer, MD, MS SECTION EDITORS **Beyond Infection Control:** The New Hospital Epidemiology Bryan P. Simmons, MD Stephen B. Kritchevsky, PhD Memphis, Tennessee Wing Hong Seto, MD Hong Kong **Disinfection and Sterilization** William A. Rutala, PhD, MPH Chapel Hill, North Carolina **Emerging Infectious Diseases** Larry J. Strausbaugh, MD Portland, Oregon Robert W. Pinner, MD Atlanta, Georgia From the Laboratory Marcus Zervos, MD Royal Oak, Michigan Fred C. Tenover, PhD Atlanta, Georgia Information Management John A. Sellick, DO Buffalo, New York The International Perspective Mary D. Nettleman, MD, MS Richmond, Virginia Issues in Surgery James T. Lee, MD, PhD St. Paul, Minnesota **Medical News** Gina Pugliese, RN, MS Chicago, Illinois Martin S. Favero, PhD Irvine, California **Practical Healthcare Epidemiology** Loreen A. Herwaldt, MD Iowa City, Iowa SHEA News Murray D. Batt, MD Clarksburg, West Virginia Statistics for Hospital Epidemiology David Birnbaum, PhD, MPH Sidney, British Columbia, Canada **Topics in Long-Term Care** Philip W. Smith, MD Omaĥa, Nebraska **Topics in Occupational Medicine** David Weber, MD, MPH Chapel Hill, North Carolina

Vice President/Group Publisher Richard N. Roash Publisher John C. Carter Editorial Director Jennifer Kilpatrick Production Editor Shirley P. Strunk, ELS

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

EDITORIAL ADVISORY BOARD

Jacques F. Acar, MD J. Wesley Alexander, MD Paul Arnow, MD Graham A.J. Ayliffe, MD Neil L. Barg, MD Elizabeth Ann Bolyard, RN, MPH, CIC John M. Boyce, MD Professor Dr. Ilja Braveny Charles Bryan, MD Christian Brun-Buisson, MD Donald E. Craven, MD Sue Crow, MSN, RN, CIC Franz Daschner, MD Leigh G. Donowitz, MD Charles E. Edmiston, Jr., PhD Theodore C. Eickhoff, MD Bruce Farber, MD Victoria J. Fraser, MD Peter C. Fuchs, MD, PhD Richard A. Garibaldi, MD Velvl Greene, PhD, MPH Robert Gaynes, MD David W. Gregory, MD David K. Henderson, MD Peter N.R. Heseltine, MD Karen Hoffmann, RN, CIC, MS Marguerite McMillan Jackson, RN, PhD Janine Jagger, MPH, PhD William R. Jarvis, MD Douglas S. Kernodle, MD Robert H. Latham, MD Lewis B. Lefkowitz, MD Hsieh-Shong Leu, MD, MSc Jack Levy, MD Victor Lorian, MD Dennis G. Maki, MD Professor Dr. Walter Marget William J. Martone, MD Allison McGeer, MD John E. McGowan, Jr., MD Jonathan L. Meakins, MD, DSc Raf Mertens, MD Robert R. Muder, MD Joseph M. Mylotte, MD, CIC Lindsay Nicolle, MD Juhani Ojajärvi, MD Michael T. Osterholm, PhD, MPH Jan Evans Patterson, MD Sindy M. Paul, MD Michael A. Pfaller, MD Samuel Ponce de Leon, MD, MSc Isaam Raad, MD Manfred L. Rotter, MD, DipBact Theodore Sacks, MD William E. Scheckler, MD Kent Sepkowitz, MD Denis Spelman, MD Michael L. Tapper, MD Clyde Thornsberry, PhD Professor Leonid P. Titov Timothy R. Townsend, MD Antoni Trilla, MD, PhD Professor Wang Shu-Qun J. John Weems, Jr., MD Robert A. Weinstein, MD Professor Dr. W. Weuffen Sergio B. Wey, MD Rebecca Wurtz, MD

Paris, France Cincinnati, Ohio Chicago, Illinois Birmingham, United Kingdom Yakima, Washington Atlanta, Georgia Providence, Rhode Island Munich, Federal Republic of Germany Columbia, South Carolina Creteil, France Boston, Massachusetts Shreveport, Louisiana Freiburg, Federal Republic of Germany Charlottesville, Virginia Milwaukee, Wisconsin Denver, Colorado Manhasset, New York St. Louis, Missouri Black Butte, Oregon Farmington, Connecticut Beer Sheva. Israel Atlanta, Georgia Nashville, Tennessee Bethesda, Maryland Los Angeles, California Chapel Hill, North Carolina San Diego, California Charlottesville, Virginia Atlanta, Georgia Nashville, Tennessee Nashville, Tennessee Nashville, Tennessee Taipei, Taiwan Brussels, Belgium Bronx, New York Madison, Wisconsin Munich, Federal Republic of Germany Bethesda, Maryland Toronto, Ontario, Canada Atlanta, Georgia Montreal, Quebec, Canada Brussels, Belgium Pittsburgh, Pennsylvania Buffalo, New York Winnepeg, Manitoba, Canada Helsinki, Finland Minneapolis, Minnesota San Antonio, Texas Trenton, New Jersey Iowa City, Iowa Mexico City, Mexico Houston, Texas Vienna, Austria Jerusalem, Israel Madison, Wisconsin New York City, New York Prahran Victoria, Australia New York, New York Brentwood Tennessee Minsk, Republic of Belarus Millwood, Virginia Barcelona, Spain Beijing, People's Republic of China Greenville, South Carolina Chicago, Illinois Greifswald, Federal Republic of Germany São Paulo, Brazil Evanston Illinois

SLACK Incorporated 6900 Grove Road Thorofare, New Jersey 08086 (609) 848-1000 Assistant Editor Eileen C. Anderer

Circulation Manager Lester J. Robeson, CCCP Production Director Christine Malin Production Coordinator Joanne Patterson Publishing Director/ Advertising Wayne McCourt Pharmaceutical Group Sales Director Michael LoPresti Advertising Sales Representative Jennine Kane Classified/Recruitment Sales Manager Michele Burch

"Synergism."

Synergism is the working relationship between two ingredients which results in performance superior to that achieved by each ingredient working separately.

Synergism is Sporicidin. Glutaraldehyde combined with an alkaline phenate system produces superior disinfecting properties.* Patented Sporicidin disinfects with substantually less glutaraldehyde than other products.

> Synergism makes Sporicidin tuberculocidal in only ten minutes at room temprature, 68° F and above, when diluted 1:16. Other alkaline glutaraldehyde products cannot be diluted and/or require longer contact times with heating to 77°F.

> > Sporicidin fulfills the CDC definition of high level disinfection using the lowest concentration of glutaraldehyde... because of Synergism.

 Journal of Clinical Microbiology, November 1985, p. 735 - 739



poricidin INTERNATIONAL

© Old Georgetown Road, Rockville, Maryland 20847



Leading the way to...

Provides a safer environment to reduce the risk of needle-stick injuries

From injection to disposal, CARPUJECT protects you from accidental needle sticks by minimizing exposure to contaminated needles.

Chosen for safety by nurses nationwide

In a national survey, nurses overwhelmingly preferred CARPUJECT over Tubex ** for protection from patients' blood. CARPUJECT was also preferred in all of 8 other criteria, ranging from convenience to efficiency.

Safer and more efficient than ampules and multi-dose vials

CARPUJECT increases efficiency and decreases risks with a sterile, accurate unit dose.

Winthrop Pharmaceuticals Division of Certing Drug Ind New York, NY 10016 CIDEX* is safe for scopes. Don't take our word for it.

Taketheirs. Karl Storz Circon ACMI **Circon ACMI** Pentax Olympus Fujinon

Major scope manufacturers have always recommended CIDEX* Activated Dialdehyde Solution.† Research and more than 20 years of actual use have shown that nonsurfactant CIDEX Solution safely disinfects delicate fiberoptic equipment. *Take their word for it: When it comes to scopes, there's no safer high-level disinfectant available.* CIDEX. We go back a long way.

Johnson + Johnson MEDICAL INC.